Over the past 5 years, the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) has continued its upward trajectory in cancer research excellence and service to its catchment area. The WFBCCC catchment area includes the Piedmont and southern Appalachia, a region of 58 contiguous counties in North Carolina, Virginia, West Virginia and Tennessee. The majority of this region is rural and exhibits significant racial health disparities. Elevated age-adjusted smoking rates, obesity rates, cancer incidence, and cancer mortality are observed across the WFBCCC catchment area when compared with the rest of the U.S. To target these issues, the WFBCCC conducts cutting-edge basic, clinical, and population research on the prevention, detection and treatment of cancer, and translates this knowledge into strategies to improve patient outcomes and reduce the incidence of cancer. WFBCCC cancer research funding is $37.9 million, of which over $14.9 million comes from the NCI; this represents a 25.3% increase in total cancer funding since the last CCSG renewal. Center research space under the Director?s authority increased by approximately 65,000 square feet, and the WFBCCC clinical facilities have been dramatically enhanced with the completion of the new eleven- story Cancer Hospital in 2013. This building houses all oncology inpatients and outpatients. The Center?s 127 members span the basic, clinical and population sciences and are organized into 4 Programs with substantial inter-and intra-programmatic productivity. Faculty additions enhanced tobacco control, tobacco-related cancer research, and precision medicine. Substantial investment in faculty, technology, and informatics significantly expanded cancer genomics capabilities. Enrollment of patients into treatment trials reached an all-time high in 2015, with a large increase in the number of patients enrolled in investigator-initiated trials. WFBCCC population scientists initiated exciting new efforts in cancer prevention and survivorship. Clinical scientists completed practice-changing studies in patients with glioma and lung cancer. Groundbreaking observations in prostate cancer emerged from WFBCCC inter-programmatic collaborations. WFBCCC basic science Programs continued to make high impact observations that are being translated into human therapeutics. The WFBCCC requests continued CCSG funding for 4 scientific Programs; 7 Shared Resources; 2 clinical research components; administration and leadership; planning and evaluation; and developmental funds. With these funds, a talented faculty integrated throughout the Cancer Center will make advances in the prevention, early detection, and treatment of cancer in the WFBCCC catchment area and the nation.

Public Health Relevance

The Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is a matrix Cancer Center, which serves the people of the multistate Piedmont and southern Appalachian region. The WFBCCC is the hub for clinical, basic, and population researchers focused on the prevention and early detection of cancer, developing novel cancer therapy, and improving the health of cancer survivors. WFBCCC is integral to the research mission of the Wake Forest Baptist Medical Center (WFBMC) in Winston-Salem, North Carolina, and is one of its largest research components. The WFBCCC unites the cancer research capabilities of multiple institutional units including the WFBMC, Wake Forest University and the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences. The WFBCCC serves a broad educational mission for Wake Forest University students and faculty as well as for practitioners and caregivers across the region. The WFBCCC strives to reduce cancer incidence, morbidity and mortality regionally, nationally, and internationally through cutting-edge research and treatments, education and outreach, and multi- disciplinary training.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA012197-42
Application #
9209681
Study Section
Special Emphasis Panel (NCI (K1)-A)
Program Officer
Belin, Precilla L
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2017-02-03
Budget End
2018-01-31
Support Year
42
Fiscal Year
2017
Total Cost
$2,093,036
Indirect Cost
$742,690
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833
Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731
Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073
Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208

Showing the most recent 10 out of 548 publications